About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNPhase 1NCT04448379

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

This study is a Phase Ib, open label, multi-center study of to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (Afatinib or Osimertinib) in patients with locally advanced or metasta...

Lead sponsor: Shanghai JMT-Bio Inc.•13 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Xiugao Yang

CONTACT

8021-60677906 yangxiugao@mail.ecspc.com

Rong Hu

CONTACT

8021-60673935 hurong@mail.ecspc.com

Sponsors

Lead Sponsor

Shanghai JMT-Bio Inc.

Collaborators

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

The objective of the trial is to evaluate the safety and efficacy of JMT101 combined with EGFR-TKIs (afatinib or osimertinib) in patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. This study consists of two parts (Stage I and Stage II). Stage I was a dose escalation study, and Stage II was a dose expansion study.

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Pathologically or cytologically confirmed, locally advanced or metastatic NSCLC, harboring an EGFR exon 20 insertion mutation. ( non-irradiable, non-operable);
•No previous treatment or first-line treatment failed NSCLC;
•At least 1 measurable lesion according to RECIST 1.1;
•ECOG score 0 or 1;

Exclusion Criteria

•Previously treated with EGFR antibody;
•Symptomatic brain metastasis;
•Interstitial pneumopathy;
•Known hypersensitivity to any ingredient of JMT101, afatinib, osimertinib or their excipients;
•Receiving an investigational product in another clinical study within 4 weeks;
•History of serious systemic diseases;
•History of serious autoimmune diseases;
•Pregnancy or lactating women.

Related studies

RECRUITINGPhase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06955988 · Locally Advanced or Metastatic Non-small Cell Lung Cancer

RECRUITINGPhase 2

Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects

NCT07175220 · Locally Advanced or Metastatic Non-small Cell Lung Cancer

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

NCT05132777 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: December 28, 2020Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE1

Enrollment48

Start dateJun 2020

Last updatedDec 28, 2020

Condition

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Locations shown

Sun Yat-sen University Cancer Center

Guangzhou, Guangdong

The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei

Chinese Pla General Hospital

Beijing

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 28, 2020Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions